Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
|Videos|April 7, 2011
Dr. Crawford on Moving Prostate Cancer Field Forward
Author(s)E. David Crawford, MD
Advertisement
E. David Crawford, MD from the University of Colorado Health Sciences Center on Moving the Field of Prostate Cancer Forward
Advertisement
Related to this article
Focal therapy for prostate cancer has evolved over 2 decades, with advances in imaging, patient selection, treatment modalities, and clinical trials.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5